SAN DIEGO, May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more ...

We initiate (NYSE: NYSE: OGN ) at Strong Buy w/ $26.4 PT. Organon & Co. is a diversified portfolio of Rx therapies anchored by global leadership in women's health and accelerating biosimilars. Our thesis is supported by a forecasted operational inflection , withMoretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with d ...

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - Organon is a global healthcare company primarily focused on improving the health of women [2] Recent Developments - On May 1, 2025, Organon announced a dividend cut of approximately 90%, leading to a stock price decline of more than 28% [3]

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) on behalf of Organon stockholders. Our investigation concerns whether Organon has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations o ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, inte ...

LOS ANGELES, May 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. As part of its Q1 2025 earnings release, Organon announced it was slashing its quarterly dividend by approximately 90% despite pr ...

SAN DIEGO, May 5, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, yo ...

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can prov ...

Take advantage of the currently offered discount on annual memberships and give CIP a try. The offer comes with an 11-month money guarantee , for first time members.Conservative Income Portfolio targets the best value stocks with the highest margins of safety. The volatility of these investments is further lowered using the best priced options. Our Enhanced Equity Income Solutions Portfolio is designed to reduce volatility while generating 7-9% yields.While we have not written specifically about Organon (NY ...

Sales Performance - Worldwide sales for the three months ended March 31, 2025, were $1.5 billion, a decrease of 7% compared to 2024, negatively impacted by approximately 3% or $44 million due to unfavorable foreign exchange rates [98]. - Sales in the United States increased by 11% to $412 million for the three months ended March 31, 2025, compared to $371 million in 2024 [98]. - International sales decreased by 12% to $1.1 billion for the three months ended March 31, 2025, compared to $1.25 billion in 2024 [98]. - Nexplanon sales increased by 13% to $248 million for the three months ended March 31, 2025, driven by increased demand and favorable pricing in the United States [102][103]. - NuvaRing sales declined by 43% to $22 million for the three months ended March 31, 2025, due to ongoing generic competition and increased government discount rates in the United States [104]. - Follistim AQ sales increased by 49% to $69 million for the three months ended March 31, 2025, due to a one-time buy-in and favorable discount rates in the United States [106]. - Hadlima sales reached $47 million during the three months ended March 31, 2025, reflecting continued ramp-up since its July 2023 launch in the United States [108][109]. - Atozet's loss of exclusivity negatively impacted sales by approximately $63 million during the three months ended March 31, 2025 [99]. - Ontruzant sales declined 54% to normalized levels in Brazil and lower demand in the U.S. for the three months ended March 31, 2025 [110]. - Brenzys sales decreased 39% due to the timing of international tenders in Brazil for the same period [110]. - Atozet sales fell 42% primarily due to loss of exclusivity in France and Spain, with expectations of continued decline in 2025 [112]. - Combined sales of Zetia and Vytorin decreased 4%, driven by demand decrease and pricing pressure in international markets [113]. - Cozaar and Hyzaar sales declined 18% due to decreased demand in China and Japan, along with mandatory price reductions in Japan [114]. - Singulair sales decreased 24% due to lower respiratory infections in China and reduced demand in Japan [115]. Financial Overview - Gross profit decreased 12% to $841 million for the three months ended March 31, 2025, impacted by unfavorable pricing and decreased sales [120]. - Research and development expenses decreased 14% to $96 million, primarily due to reduced clinical study activity [124]. - Restructuring costs increased to $86 million, with expected annual savings of approximately $200 million from cost-saving initiatives [126]. - Cash and cash equivalents as of March 31, 2025, were $547 million, with working capital increasing to $1.76 billion [131][132]. Market and Risk Management - No changes to market risk were reported for the quarter ended March 31, 2025 [142]. - For detailed market risk exposure, refer to the Annual Report on Form 10-K for the year ended December 31, 2024 [142]. - Recently issued accounting standards are discussed in Note 2 of the Condensed Consolidated Financial Statements [141]. Corporate Developments - The acquisition of Tofidence from Biogen includes an upfront payment of $51 million and potential milestone payments of up to $45 million based on net sales [96].